X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

China’s pharmaceutical company launches operations in U.S.

Yuvraj_pawp by Yuvraj_pawp
4th September 2014
in Asia, News

Tasly Holding Group, a leading pharmaceutical company in China, officially launched its North American operations in the state of Maryland Wednesday as part of its “go-out” efforts to further expand its business of traditional Chinese medicine overseas.

The company, which celebrated its 20th anniversary in May, held a ribbon-cutting ceremony at its office in Rockville, Maryland, to mark the official launch of Tasly Pharmaceuticals as its North American headquarters, with about 150 guests from the Maryland state government and biotechnology and pharmaceutical companies in attendance.

“Tasly has comprehensively implemented the strategy of internationalization,” Xijun Yan, chairman of Tasly, said at the ceremony. “Establishment of Tasly Pharmaceutials is one of the most important strategies that we take. We have positioned Tasly Pharmaceuticals as our overseas headquarters, with the full support provided by Tasly Group.”

He said Tasly’s products and services cover biopharmaceutical drugs, healthcare products, medical rehabilitation and health management, with a total revenue of 4 billion U.S. dollars in 2013.

“I strongly believe that our natural products will contribute to reducing the Medicare cost and effectively resolving certain healthcare-related issues of the U.S. healthcare system,” Yan said.

“China has been the leader in healing for thousands of years” and Tasly’s traditional Chinese medicine “is opening up a whole new chapter of Maryland’s life sciences community,” said Dominick Murray, Maryland’s Business and Economic Development Secretary, adding that they are “excited” to have the new Chinese investment in the state, which is home to more than 500 bioscience companies.

Tasly’s products have been approved by national health regulatory authorities in at least 34 countries.

Its Fufang Danshen dripping pill, a multi-herb-based treatment for stable angina pectoris, the medical term for chest pain or discomfort, is now in a phase three clinical trial in the U.S. and several other countries.

The company said it expected the pill to be the first ever multi-herb-based and chemical-free pharmaceutical product approved by the U.S. Food and Drug Administration.

Tasly also plans to launch Deepure, a line of nutraceuticals that are gluten-free and made without preservatives, artificial colors, flavors, sweeteners or gelatin, in the U.S. this fall.

Tags: Asia Pacific
Previous Post

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In